These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10080591)

  • 1. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.
    Bridgewater JA; Nelstrop AE; Rustin GJ; Gore ME; McGuire WP; Hoskins WJ
    J Clin Oncol; 1999 Feb; 17(2):501-8. PubMed ID: 10080591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel.
    Balbi GC; Cardone A; Passaro M; Battista M; Monteverde A; Visconti S
    Eur J Gynaecol Oncol; 2005; 26(3):285-7. PubMed ID: 15991527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?
    Davelaar EM; Bonfrer JM; Verstraeten RA; ten Bokkel Huinink WW; Kenemans P
    Cancer; 1996 Jul; 78(1):118-27. PubMed ID: 8646707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.
    Gordon AN; Granai CO; Rose PG; Hainsworth J; Lopez A; Weissman C; Rosales R; Sharpington T
    J Clin Oncol; 2000 Sep; 18(17):3093-100. PubMed ID: 10963637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Riedinger JM; Eche N; Basuyau JP; Dalifard I; Hacene K; Pichon MF
    Gynecol Oncol; 2008 May; 109(2):194-8. PubMed ID: 18329083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.
    Bruzzone M; Catsafados E; Miglietta L; Amoroso D; Pedulla F; Giannessi PG; Locatelli MC; D'Antona A; Foglia G; Mammoliti S; Turno F; Gentile A; Nicosia F; Luporini G; Ragni N; Boccardo F
    Oncology; 1996; 53(5):349-53. PubMed ID: 8784466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
    J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.
    Cantù MG; Buda A; Parma G; Rossi R; Floriani I; Bonazzi C; Dell'Anna T; Torri V; Colombo N
    J Clin Oncol; 2002 Mar; 20(5):1232-7. PubMed ID: 11870165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
    Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
    Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.
    Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO
    Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.
    Paulsen T; Marth C; Kaern J; Nustad K; Kristensen GB; Tropé C
    Gynecol Oncol; 2000 Mar; 76(3):326-30. PubMed ID: 10684705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
    Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
    Piccart MJ; Green JA; Lacave AJ; Reed N; Vergote I; Benedetti-Panici P; Bonetti A; Kristeller-Tome V; Fernandez CM; Curran D; Van Glabbeke M; Lacombe D; Pinel MC; Pecorelli S
    J Clin Oncol; 2000 Mar; 18(6):1193-202. PubMed ID: 10715288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.
    Pant AC; Diaz-Montes T; Tanner E; Ahmad S; Giuntoli RL; Holloway RW; Bristow RE
    J Chemother; 2010 Aug; 22(4):270-4. PubMed ID: 20685633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.